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Abstract
Background: About 30-60% of individuals are non-adherent to their prescribed medications and this risk increases
as the number of prescribed medications increases. This paper outlines the development of a consumer-centred
Medicine Self-Management Intervention (MESMI), designed to improve blood pressure control and medication
adherence in consumers with diabetes and chronic kidney disease recruited from specialist outpatients’ clinics.
Methods: We developed a multifactorial intervention consisting of Self Blood Pressure Monitoring (SBPM),
medication review, a twenty-minute interactive Digital Versatile Disc (DVD), and follow-up support telephone calls
to help consumers improve their blood pressure control and take their medications as prescribed. The intervention
is novel in that it has been developed from analysis of consumer and health professional views, and includes
consumer video exemplars in the DVD. The primary outcome measure was a drop of 3-6 mmHg systolic blood
pressure at three months after completion of the intervention. Secondary outcome measures included: assessment
of medication adherence, medication self-efficacy and general wellbeing. Consumers’ adherence to their prescribed
medications was measured by manual pill count, self-report of medication adherence, and surrogate biochemical
markers of disease control.
Discussion: The management of complex health problems is an increasing component of health care practice,
and requires interventions that improve patient outcomes. We describe the preparatory work and baseline data of
a single blind, randomized controlled trial involving consumers requiring cross-specialty care with a follow-up
period extending to 12 months post-baseline.
Trial Registration: The trial was registered with the Australian and New Zealand Clinical Trials Register
(ACTRN12607000044426).
Background
Comorbidity burden
The prevalence of chronic diseases continues to
increase, necessitating sustained self-management of
medications by consumers in the community and long
term monitoring by health professionals. Diabetes and
chronic kidney disease are two such rapidly escalating
global health problems [1], and diabetes is now the
most common cause of chronic kidney disease [2].
Irrespective of the cause of chronic kidney disease, the
co-existence of diabetes and chronic kidney disease pre-
sents a significant health, social and economic burden
and negatively influences health status beyond the sum
of the effects of each disease: mortality is higher, quality
of life is worse, and the burden on health care services
is increased [3].
The complexity of the treatment for co-existing dia-
betes and chronic kidney disease involves comorbidity
management, in particular hypertension, to improve dis-
ease control and health outcomes. Accordingly, the con-
sumer is required to consult with numerous health
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any medium, provided the original work is properly cited.professionals in primary and specialist settings who pre-
scribe multiple medications for consumers to manage
their health. Taking medications as prescribed is a prin-
cipal requirement for well-managed chronic diseases.
When multiple treatments are required for different
health problems, medication-related concerns such as
adherence, drug interactions and side effects, can be
perceived as more troublesome to consumers than the
treatments themselves [4,5].
Adherence can be defined as the extent to which con-
sumers follow the instructions they are given for pre-
scribed treatments [6]. Approximately 50% of
consumers do not take their medications as prescribed.
Interventions to assist medication adherence in the pre-
sence of co-existing chronic conditions have rarely been
examined in past work and this research is of a high
priority [7,8]. The management of comorbidities is an
increasing feature of health care practice.
While medical interventions are very important to
manage and prevent further health problems in people
with co-existing diabetes and chronic kidney disease,
long-term health outcomes depend on the effectiveness
of the choices that consumers make for themselves on
a daily basis [9]. The quality of shared decision making
between health professionals is critical to this process.
Medication mismanagement and safety are a cause of
great stress and cost to healthcare providers worldwide
[10,11]: 3% of all hospital admissions relate to over-
use, under-use and inappropriate use of medications
[10]. Poorly controlled diabetes and chronic kidney
disease lead to blood vessel injury resulting in heart
failure, loss of vision, total kidney failure, and limb loss
that disrupt the consumer’s ability to engage in inde-
pendent activities of daily living. This paper outlines
t h em e t h o d o l o g yo fac l i n i c a lt r i a lu s i n gt h eC O N -
SORT Statement [12], which is designed to help con-
sumers with diabetes and chronic kidney disease
control their blood pressure and to take their medica-
tions as prescribed.
Conceptual framework
The conceptual framework underpinning this project is
the modified Health Belief Model (HBM) [13,14]. The
model explains short- and long-term health behaviours
by focusing on the attitudes and beliefs of individuals,
and their perceived threat and net benefits of taking
positive health-related action. The modified HBM is
based on the understanding that people will take a
recommended health action if they believe the action
will avoid a negative health condition and they have the
confidence or self-efficacy to undertake the action. The
five concepts of the modified HBM include: perceived
susceptibility to a particular health problem, the severity
of the health problem, the benefits and barriers to tak-
ing positive health-related action, and self-efficacy [15].
These concepts account for people’s readiness to act.
The HBM model encompasses modifying or enabling
psychosocial influences that affect a consumer’sa d h e r -
ence to recommended health actions.
Methods
Overview of the study
This trial was designed to improve medication self-man-
agement in consumers with co-existing diabetes and
chronic kidney disease by testing a multifactorial, consu-
mer-centred intervention to improve systolic blood pres-
sure control and medication adherence in a randomized
controlled trial (RCT). Consumer-centred interactive
interventions to aid decision-making are an effective
way of helping consumers with diverse backgrounds to
understand their chronic diseases and complex medica-
tion regimens [16].
Study design
The study is a single-site, single-blind, longitudinal RCT.
Participants have been allocated to one of two groups:
the intervention group receives a multifactorial interven-
tion designed to improve blood pressure control and
medication adherence, and the control group receives
standard care offered by the treating hospital’s outpati-
ent clinics and primary care provided by the partici-
pants’ general practitioner. Data are collected at four
time points: enrolment baseline data collection (T1),
immediately following delivery of the intervention (T2),
three months post-intervention (T3) and 9-months
post-intervention (T4).
Study aims
The primary aim of the study were to evaluate the effec-
tiveness of a multifactorial intervention in terms of
improved systolic blood pressure control in participants
with co-existing diabetes and chronic kidney disease.
Secondary aims were to determine the effectiveness of
the intervention on medication adherence, medication
self-efficacy and general wellbeing in consumers with
co-existing diabetes and chronic kidney disease. The
extent of the relationship between pill counts, self-report
of medication adherence and self-efficacy, and other
clinical and surrogate biochemical markers of disease
control will also be evaluated.
Study hypotheses
1. Compared to participants receiving standard care,
participants with diabetes and chronic kidney disease
who receive the intervention will show greater reduction
in blood pressure at three months post-intervention
(T3).
2. Compared to participants receiving standard care,
participants with diabetes and chronic kidney disease
who receive the intervention will show a greater adher-
ence to their prescribed medication regimen at three
months post-intervention (T3).
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with increased systolic blood pressure control at three
months post-intervention (T3).
The intervention
Information derived from the literature and other com-
ponents of the study were used to develop a multifactor-
ial intervention, the Medicine Self-Management
Intervention (MESMI) to improve blood pressure con-
trol and medication adherence. The MESMI consisted
of self-monitoring of blood pressure, an individualised
medication review, a twenty-minute Digital Versatile
Disc (DVD), and fortnightly follow-up telephone contact
for 12 weeks to support blood pressure control and
optimal medication self-management. All components
of the intervention were delivered by a renal specialist
nurse with doctoral qualifications trained in motiva-
tional interviewing using a checklist and standing script
for fidelity purposes.
Self-monitoring of blood pressure
The intervention nurse taught participants in the inter-
vention group to take their own blood pressure using
the self blood pressure measurement (SBPM) guidelines
of O’Brien et al. [17] and a clinically validated A&D
Medical Pty. Ltd. digital blood pressure monitor (Model
UA-787, Japan). Participants were asked to take their
blood pressure seated every morning on their non-
dominant arm at around the same time after waking
before they had their morning antihypertensive medica-
tions. Participants were informed that their blood pres-
sure may be higher at this time as they had not yet had
their antihypertensive medications for the day. Partici-
pants were provided with a booklet to record their daily
blood pressures for approximately three months.
Medication review
The individualised medication review involved the inter-
vention nurse drawing up a chart of the participant’s
prescribed medications as documented by the research
assistant at the enrolment visit (T1), which included the
generic and brand name of the medication, what the
medication was for, the dose and when to take it, and
targets for which to aim. Targets included a blood pres-
sure ≤130 mmHg, blood glucose of < 7 mmol/L, Hb
A1C < 7%, and low density lipoprotein (LDL) cholesterol
< 2.5 mmol/L as recommended by Harris [18]. Prescrip-
tion reconciliation, the process of comparing the partici-
pant’s reported medication regimen to all of the
medications that the participant has been taking, was
conducted. Any areas of ambiguity with what partici-
pants thought they should be taking compared with
what was prescribed according to pill containers and
medication lists were sorted prior to obtaining agree-
ment of the prescription. For example, one participant
was taking duplicate cholesterol-lowering drugs that
were the same but had different brand names. The
medication chart was left with the participants as their
personal medication record to take to medical consulta-
tions if they did not have a current medication list, and
to note changes in their prescriptions as they occurred.
DVD development
The DVD involved an interactive, psychosocial approach
to motivating people to take their medications, appeal-
ing to knowledge, thoughts and feelings, underpinned by
the modified Health Belief Model [15]. By focusing on
the attitudes and beliefs of individuals, we believed a
person would be more likely to take their medications
as prescribed if they understood the inter-relationship of
their conditions, in particular hypertension, and if their
confidence in independently managing their health was
improved.
The content of the DVD was drawn from analysis of
medication adherence from the perspectives of consu-
mers with co-existing diabetes and chronic kidney dis-
ease and health professionals likely to care for this
group [19]. Knowledge of these aspects is likely to facili-
tate effective communication between consumers and
health professionals, and contribute to medication safety
and improved wellbeing [20]. The DVD comprised three
sections: how blood pressure affects the body; the need,
benefit and safety of prescribed medications; and tips to
help consumers take their medications as prescribed.
Video clips of participants with co-existing diabetes and
chronic kidney disease not involved in the RCT who
were willing to share their experiences with taking mul-
tiple medications were incorporated into each section.
These participants talked about how they managed their
medication regimens on a daily basis to facilitate medi-
cation adherence using a psychosocial approach. As a
result it was hypothesized that participants in the trial
would control their blood pressure and learn effective
medication self-management skills.
The content of the DVD was checked against informa-
tion in the public arena to ensure a consistent message
was being conveyed. We also made sure that the text
could easily be read by consumers with visual impair-
ment (≥ 24 Arial font) and understood at a Year 8 level.
The DVD was developed under guidance of the project
team and a reference group drawn from the key stake-
holders of participants and health professionals engaged
in the research.
The DVD underwent formative evaluation for internal
validity by nine health professionals, one educational
expert, and one consumer who provided video footage.
Content, readability (flow, clarity, language, layout), and
appropriateness of information to meet the learning
objectives and desired outcomes were critically evaluated
using the Content Validity indices [21], which were
respectively 0.98, 0.95 and 0.97. These values exceeded
the parameter of 0.83 for item acceptability. Overall,
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editorial suggestions. Advice was also obtained on
screen design features and navigation of the interface,
which were incorporated into the final version. The
DVD was produced by the university’s biomedical multi-
media unit incorporating educational design expertise.
Motivational interviewing telephone calls
Fortnightly telephone calls were planned after the inter-
vention home visit until follow-up at 3-months post-
baseline (T2). Each call was conducted using the princi-
ples of motivational interviewing by the intervention
nurse to promote medication adherence, adapted from
the guidelines of Dilorio et al. [22]. The telephone call
commenced with an open-ended question inquiring
about the participants’ wellbeing. An enquiry about their
blood pressure followed, whereby participants reported
their blood pressure readings for discussion. A general
enquiry was then made about their medications, such as
whether any changes were made to their medications, if
they experienced any side effects or difficulties taking
their medications, if they have any concerns with doc-
tors’ visits and if they had any questions regarding their
health.
The participants’ motivation and confidence in taking
their medications was then assessed out of a score of 1
to 10, using this information to elicit barriers, concerns
and positive self-motivational statements. A summary of
these comments was presented back to the participant,
inviting any further comments using reflective and nor-
malising statements where appropriate to elicit problem-
solving. The participants was then asked to identify
three goals they would like to achieve in the next five
years to help link their medication adherence to their
life. They were also asked to briefly explore connections
between their current medication-taking behaviour and
their ability to achieve these goals. A summary was pre-
sented back to the participants, incorporating sugges-
tions to overcome identified difficulties and affirming
desired behaviour. The participants were asked if they
had any queries which were addressed, and the call was
concluded after thanking the participants for their time
and interest. The remaining motivational interviewing
calls followed a similar format that incorporated follow-
up of suggestions or queries made in previous calls.
Usual care
Participants randomized to the usual care control group
received standard care offered to patients with co-exist-
ing diabetes and chronic kidney disease attending the
diabetes and nephrology outpatients’ clinics at the hos-
pital and primary care offered by their general practi-
tioners. Our definition of standard care is the ongoing
medical care provided to a patient with co-existing dia-
betes and chronic kidney disease attending routine out-
patient clinic follow up, which has been reported
elsewhere [23]. Data were collected from the usual care
group at the same time points as the intervention group.
Feasibility of study
In the planning stages of the study in 2006, we found
that more than 1,400 patients with diabetes at the hospi-
tal where recruitment was to take place had urine
microalbumin/creatinine ratios ranging from 2 to an
extreme of 6020 mg/mmol, with an average microalbu-
min/creatinine ratio of 97 mg/mmol suitable for our
recruitment purposes. Additionally, the renal depart-
ment at the hospital is one of the largest renal services
in Australia treating in excess of 2,300 patients annually
with chronic kidney disease. The base rate of systolic
blood pressure control > 130 mmHg in the nephrology
outpatient clinic population was estimated to be about
50%.
Setting and recruitment
A research assistant who was a qualified registered
nurse recruited from the diabetes and nephrology outpa-
tient clinics of a metropolitan hospital in Melbourne
commencing in August 2008. This research assistant
conducted all data collection for the study and was a
different person to the intervention nurse. There were
two diabetes clinics per week for patients requiring
ongoing review with approximately 50 patients booked
in per clinic. If the patient did not have hypertension,
they were immediately deemed ineligible irrespective of
the presence of renal disease. There was one renal clinic
per week with approximately 50 patients booked in of
whom about 15 had either type 1 or type 2 diabetes.
Participants were also recruited from a combined dia-
betes and nephrology clinic (NephDiab clinic) estab-
lished to incorporate both diabetes and nephrology
specialist review within the same appointment where
approximately 20 patients were booked in every month.
Patients who met the inclusion criteria were approached
by the research assistant and asked if they wanted to
participate in a study designed to help them understand
and manage their complex medical conditions and pre-
scribed medications better.
Patient eligibility
The inclusion criteria for the MESMI study are listed in
Table 1. The primary outcome was systolic blood pres-
sure control, taken by the research assistant who was
trained to take blood pressure according to accepted
guidelines [17] using an Accosson mercury desk sphyg-
momanometer and 3M™ Littmann classic 11 S.E. stetho-
scope. Participants were to avoid smoking, exercise and
caffeine for 30 minutes while they were waiting for their
clinic consultation and were seated for approximately
five minutes prior to having their blood pressure
measured.
The participant’s blood pressure was taken by the
research assistant five times at recruitment, commencing
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blood pressure measurement was then repeated twice
on the arm with the lower systolic blood pressure at
one minute intervals. These two blood pressure readings
were then averaged, and the mean measure was used to
check the presence of hypertension. Finally, the standing
blood pressure was then taken on the same arm within
three minutes to detect the presence of orthostatic
hypotension, a common side effect of antihypertensive
medications in the older population [17].
Consumers who were not mentally competent
(assessed by a score of < 6 on the Abbreviated Mental
Test) [24], had an unstable mental illness, or did not
understand the English language sufficiently were
excluded. Proficiency in spoken English was assessed by
asking participants from non-English speaking back-
grounds how well they spoke English using a four-point
scale ranging from very well to not at all [25]. Persons
who spoke English not well who had a support person
with a good command of the English language were
included whereas persons who scored ‘not at all’ on the
Proficiency in Spoken English Test, irrespective of the
presence of support persons who spoke English, were
excluded from the trial.
Ethics approval and data and safety monitoring
Prior to commencing the study, ethics approval was
sought and granted from the Human Research Ethics
Committees of the participating hospital (HREC Project
No: 2006.239) and university (Ethics ID: 0713622). The
trial was prospectively registered with the Australian
and New Zealand Clinical Trials Register (ANZCTR)
before recruitment of the first participant (Registration
number ACTRN12607000044426). Written informed
consent was obtained from participants prior to enrol-
ment. The study was conducted according to the proto-
col and under ethical guidelines of the National Health
and Medical Research Council of Australia [26]. Regular
weekly meetings were held between members of the
research team to discuss issues relating to the progress
of the trial.
Enrolment and randomization
Participants who expressed an interest in participating
and who met the inclusion criteria were contacted by
the research assistant by telephone to organize a home
visit. At the home visit, formal informed consent was
obtained prior to collecting demographic, social and
medical data, sitting blood pressure according to
accepted guidelines [17] (taken twice on the arm with
the lowest reading a minute apart and averaged), body
mass index, comorbidity burden, baseline surveys and
pill counts (Table 2). The baseline visits lasted approxi-
mately 1 1/4 hours each.
All participants have data collected at four points in
time (Table 2): baseline (T1), 3-month following the
baseline data collection and at completion of the inter-
vention (T2), and 6- (T3) and 9-months (T4) post-inter-
vention (12-months post-baseline data collection).
Table 1 Inclusion and exclusion criteria for the MESMI
study
Inclusion criteria
* Patients of either gender aged ≥ 18 years of age
* Able to comprehend English (English proficiency test > Not at all)
* Mentally competent (Abbreviated Mental Test score > 6)
* Type 1 or Type 2 diabetes recorded in patient’s medical record
* Chronic kidney disease defined by an estimated Modified Diet in
* Renal Disease glomerular filtration rate (MDRD-eGFR) of ≤ 60 mL/
min/1.73 m
2 and/or:
* Diabetic kidney disease defined by Malb/Cr ratios > 2.0 mg/mmol
for men, > 3.5 mg/mmol for women or an elevated 24 hour urine
albumin of > 30 mg over 24 hours
* Systolic hypertension ≥130 mmHg for the previous two clinic visits
& prescribed antihypertensive medication/s
Exclusion criteria
* Impending dialysis defined by an eGFR less than 15 mL/min/1.73
m
2
* Pregnancy
* A new diagnosis of cancer
* A mental illness not stabilized with medication
Table 2 Schedule of data collected from consumers at
each data collection point
Measures T1 T2 T3 T4
Demographics(age,
gender, education,
usual role, social
support)
X
English proficiency X
Abbreviated mental
health test
X
Chronic conditions X
Prescribed
medications
X
Body Mass Index X X
Blood pressure X X X X
SF-12v2-Item Health
Survey
XXXX
MASES Self-Efficacy
Scale
XXXX
Morisky scale X X X X
Health care
utilisation scale
XXXX
Pill count X X X X
Serum & urine
laboratory measures
ie eGFR, urine Malb/
Cr ratios, creatinine,
Hb, HbA1C, CaPO4,
lipids
XXXX
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of medication adherence taken as part of the partici-
pant’s standard treatment such as eGFR, urine microal-
bumin/creatinine ratios, serum creatinine, Hb, Hb A1C,
CaP04 and low-density lipids are collected at these four
time points from the participant’s medical records. Fol-
low-up is projected to continue until July 2010.
Instruments
The Morisky Medication Adherence Scale [27] was used
to measure adherence to all prescribed medications, has
four questions with ‘yes’ and ‘no’ responses and a Cron-
bach’s a coefficient of 0.62. The Medication Adherence
Self-efficacy Scale (MASES) [28] has 26 questions identify-
ing difficult situations affecting medication self-efficacy,
with ‘not at all sure’, ‘somewhat sure’ and ‘very sure’
answers, takes about five minutes to complete and has a
Cronbach’s a coefficient of 0.95. The Short Form (SF)-12,
12 item Health Survey (version 2) [29], was used to mea-
sure general wellbeing, has five choices of responses and
takes approximately two minutes to complete. Cronbach’s
a coefficients for the SF-12 closely mirror that of the SF-
36 at 0.89 and 0.76. The Health Care Utilization (HCU)
[30] Scale has four items of health care, for example, visits
to a doctor, where participants have to indicate the num-
ber of times they used the service in the past three
months, and takes approximately two minutes to com-
plete. The HCU has a test-retest reliability of.0.91 [9].
Pill counts
Pill counts were conducted at T1, T2, T3 and T4 time
points according to the process outlined by Haynes et
al. [31]. At enrolment, participants were asked to keep
their empty pill containers for the duration of the study.
On each data collection home visit, participants were
invited to present all their prescribed medications which
were manually counted. The prescribed regimen off the
container, the dispensing pharmacy, the number of
tablets dispensed and the dispensing date for all tablets
was recorded. The participants were asked if they kept
their medications anywhere else (for example, a dupli-
cate supply), and these were also counted and recorded.
The participants were asked if they started taking pills
from the containers on hand on the dispensing date, or
if not, when they did start taking the medication from
the container.
Pill counts were estimated by dividing the number of
pills missing from the containers by the number of pills
which should be missing if the participant had taken all
medications as prescribed [31]. This figure was then
multiplied by 100 to obtain a percentage score. For
example, Adherence A = (# of pills taken/#of total
doses) × 100. When more than 100% was calculated,
Adherence B was calculated, which was: Adherence B =
100 - (Adherence A -100): if Adherence A was 120%,
Adherence B was 80% [32].
Medication adherence was set at ≥80% as the minimum
acceptable level for each prescribed medication, a com-
monly accepted cut-off point for defining a therapeutic
level of medication adherence [33]. Insulin with different
devices was hard to quantify when we did not have the
resources to buy equipment to weigh the insulin. We
decided to use serum blood glucose, HbA1C and evidence
of hypoglycaemic and hyperglycaemic episodes requiring
hospitalization as evidence of medication nonadherence.
Random assignment and blinding
Following the baseline visit, a statistician off-site con-
ducted the centralized, stratified block randomization of
participants according to age, gender and baseline systolic
blood pressure to maintain allocation concealment and to
prevent selection bias. The identity of all participants who
were randomized to receive the intervention was kept in a
locked cabinet in the leading researcher’s locked office
according to university and hospital ethics approval. Data
collection conducted by the research assistant was blinded
to the intervention group. At the 9-month visit (T4), parti-
cipants will be asked if they think they received standard
care or the intervention or were unsure and why [34].
However, participants in the intervention group could not
be blinded as the intervention was delivered face-to-face
and it would be expected that this group would accurately
guess their group assignment. Participants in either group
received no remuneration for participation.
Power analysis
We based our sample size on Gerin et al.’s [35] medica-
tion adherence and blood pressure control (ABC)
research, using the standard deviation for systolic blood
pressure of 12.1 mmHg cited in the usual care systolic
blood pressure group. The sample size determined to
allow the detection of a mean (± SD) difference in systo-
lic blood pressure of 3-6 mmHg between the interven-
tion and control groups. The sample size calculation has
yielded 51 participants per group with 80% power (a =
0.05 [one-tailed], including 5% attrition, totalling 108
participants in all.
Participant flow
Recruitment commenced on the 27th August 2008 and
ceased on 17
th June 2009. A total of 111 participants
were recruited and baseline data taken. The enrolment
baseline visits commenced on the 8
th September 2008
and ceased on 22
nd June 2009. Participant flow is shown
in Figure 1.
Data analysis
The analysis will be performed on an intent-to-treat
basis. All data will be entered into an ACCESS data-
base by a second research assistant who is blinded to
the intervention group. An experienced biostatistician
will check the integrity of the database and conduct
statistical analyses. Descriptive statistics will be used to
summarise demographic, social and medical data
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any effect of these variables on primary and secondary
outcomes. Baseline characteristics of the intervention
and usual care groups will be compared. Blood pres-
sure, medication adherence, medication self-efficacy,
and general wellbeing between the usual care and
intervention groups will be compared to assess the
effects of the intervention between groups and within
participants at T2, 3 and 4 using t-tests as appropriate.
The various measures of medication adherence will be
examined for correlations. Continuous variables that
are not normally distributed will be examined using
equivalent non-parametric tests. Differences in change
in binary categorical variables within each group will
be analysed using McNemar’s test and the changes
between the two groups will be assessed by chi-
squared tests for trends. Potential confounders may
include comorbidities and number of prescribed medi-
cations. Statistical significance will be determined with
p values of < 0.05.
Discussion
This trial involves an evaluation of the effectiveness of a
multifactorial intervention developed from analysis of
medication adherence from the perspectives of consu-
mers with co-existing diabetes and chronic kidney dis-
ease and multidisciplinary health professionals likely to
be involved in their management. This approach was
chosen to foster effective communication and partner-
ships with health professionals necessary for improved
medication adherence and patient health outcomes. The
major strength of this trial is that it is one of the first
published studies to tackle the problem of competing
comorbidity management where consumers are required
to consult with multiple health practitioners and take
multiple prescribed medications.
Recruitment difficulties
The inclusion criteria presented difficulties, particularly
in relation to pathology results recorded in the patient’s
electronic or hard copy of their medical record to deter-
mine eligibility. Although patients had diabetes and
Figure 1 Trial participant flow.
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tinely have microalbumin/creatinine ratios or less com-
monly, 24 hour urine albumins taken. Additionally,
some estimated glomerular filtration rates were recorded
as ‘≥ 60’ or ‘<9 0 ’ depending on the point-of-care, and if
patients did not have a microalbumin/creatinine ratio
recorded in their history, they were excluded. Therefore,
we have recruited participants with co-existing diabetes
(Type 1 or 2) and microalbumin/creatinine ratios > 2.0
mg/mmol for men, > 3.5 mg/mmol for women or co-
existing diabetes (Type 1 or 2) and chronic kidney dis-
ease (eGFR ≤ 60 mL/min/1.73 m
2). The development,
dissemination and implementation of chronic kidney
disease clinical practice guidelines that harmonize with
other specialties are needed to improve patient out-
comes of chronic kidney disease [36]. We also changed
the inclusion criteria to systolic hypertension ≥130
mmHg for the previous clinic visit rather than the pre-
vious two clinic visits to improve the rate of recruit-
ment. These deviations and rationales have been
documented with the ANZCTR. Our experience has
shown that it is essential to pilot recruitment when
funding limitations constrain the time period to run a
RCT.
Another unforeseen problem affecting recruitment was
a change in the organization of the diabetes outpatient
clinics. Since commencing the study, patients with dia-
betes were ‘handed over’ to their general practitioners to
manage in primary care rather than attend routine three
monthly hospital outpatient clinic follow-up (these out-
patient clinics were reduced to annual review), effec-
tively reducing the pool of patients from which to
recruit.
At recruitment, we found a significant number of par-
ticipants spoke a language other than English, most
commonly Greek and Italian, who were excluded from
the trial because they did not speak English. The latest
Australian census shows that one quarter of Australians
are born overseas [37], and consumers from culturally
and linguistically diverse backgrounds have an increased
risk of medication mismanagement [38]. In addition,
123 patients who met the inclusion criteria refused the
opportunity to participate and a further 40 patients who
met the inclusion criteria did not turn up for their
scheduled appointment. A run-in period would have
alerted us to these difficulties and enabled us to intro-
duce strategies to enhance recruitment, such as clinic
appointment reminders and reimbursement for
participation.
Assessing medication adherence
Another problem was objective evaluation of medication
adherence. The cost of electronic pill monitoring for
multiple medications was prohibitive. Difficulties with
manual pill counts included the sheer number of
medications that the participants had on hand. Very few
participants could recall when they started their new
prescriptions. Some participants were found to have six
boxes of the same medications, all of which had been
partially used. In another case, a husband and wife
shared their prescribed medications, upsetting the
count. Many had different storage areas for medications
that were not currently prescribed, in addition to com-
plementary medications. There were discrepancies
between what participants said verbally and what was
being counted by the research assistant. For example,
participants stated that they had not missed any pills
but their scripts had ran out, and they were found to
have missed at least one or two pills or there were more
medications counted that should have been taken. One
participant admitted to fiddling with her medications,
and took gliclazide 80 mg and gliclazide MR 30 mg on
alternate days as she was not sure ‘which one was bet-
ter’. Participants also decanted from one container into
a n o t h e r .I no n ei n s t a n c e ,t h e r ew e r e6 5p i l l si nac o n -
tainer that should have had 50 pills in it. Our research
has emphasized the need for an objective, affordable
method to monitor adherence to multiple prescribed
medications.
Despite these issues, the management of comorbidities
is an increasing component of health care practice, and
as such, is in need of interventions that improve patient
outcomes. This research has highlighted the need for
quality medical record documentation and a systematic,
evidence-based approach to patient care that overrides
the needs of specialties in the patient with competing
diagnoses.
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